163.34 USD
+1.01 (+0.62%)
163.34 USD
0 (0%)
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 58 industry peers in the Life Sciences Tools & Services industry. RGEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year RGEN was profitable.
- In the past year RGEN had a positive cash flow from operations.
- Of the past 5 years RGEN 4 years were profitable.
- Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 0.06%, RGEN is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
- RGEN has a Return On Equity of 0.08%. This is in the better half of the industry: RGEN outperforms 70.69% of its industry peers.
- The Return On Invested Capital of RGEN (1.05%) is comparable to the rest of the industry.
- RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
- The Profit Margin of RGEN (0.25%) is better than 68.97% of its industry peers.
- RGEN's Operating Margin of 6.58% is fine compared to the rest of the industry. RGEN outperforms 62.07% of its industry peers.
- RGEN's Operating Margin has declined in the last couple of years.
- RGEN has a Gross Margin of 51.59%. This is comparable to the rest of the industry: RGEN outperforms 58.62% of its industry peers.
- RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
- The number of shares outstanding for RGEN has been increased compared to 1 year ago.
- RGEN has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RGEN has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 7.42 indicates that RGEN is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 7.42, RGEN belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
- The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
- RGEN's Debt to FCF ratio of 5.05 is fine compared to the rest of the industry. RGEN outperforms 67.24% of its industry peers.
- A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
- RGEN has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.42 |
ROIC/WACC0.1
WACC10.75%
2.3 Liquidity
- A Current Ratio of 8.36 indicates that RGEN has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 8.36, RGEN belongs to the best of the industry, outperforming 91.38% of the companies in the same industry.
- A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
- RGEN has a Quick ratio of 7.14. This is amongst the best in the industry. RGEN outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 21.17% over the past year.
- The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
- The Revenue has decreased by -8.54% in the past year.
- RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
- The Earnings Per Share is expected to grow by 24.54% on average over the next years. This is a very strong growth
- Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.92% on average per year.
EPS Next Y14.84%
EPS Next 2Y19.33%
EPS Next 3Y22.24%
EPS Next 5Y24.54%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.31%
Revenue Next 5Y15.92%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- RGEN is valuated quite expensively with a Price/Earnings ratio of 98.40.
- RGEN's Price/Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 27.25, RGEN is valued quite expensively.
- The Price/Forward Earnings ratio is 77.50, which means the current valuation is very expensive for RGEN.
- RGEN's Price/Forward Earnings is on the same level as the industry average.
- When comparing the Price/Forward Earnings ratio of RGEN to the average of the S&P500 Index (25.98), we can say RGEN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.4 | ||
| Fwd PE | 77.5 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
- The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 86.35 | ||
| EV/EBITDA | 80.44 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- RGEN's earnings are expected to grow with 22.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.63
PEG (5Y)13.85
EPS Next 2Y19.33%
EPS Next 3Y22.24%
5. Dividend
5.1 Amount
- RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status for RGEN stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the financial health of REPLIGEN CORP (RGEN) stock?
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
What is the earnings growth outlook for REPLIGEN CORP?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.